GS-5245 for Coronavirus

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Coronavirus+3 MoreGS-5245 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The goal of this study is to test if GS-5245 is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a high risk of developing serious or severe illness. The study will also measure how much GS-5245 gets into the blood and how long it takes the body to get rid of it.

Eligible Conditions
  • Coronavirus

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: First dose date up to Day 5 plus 30 days

Baseline, Day 5
Change From Baseline In Viral Load
Day 29
COVID-19 Testing
Proportion of Participants With All-cause Death at Day 29
Proportion of Participants With All-cause Hospitalization by Day 29
Proportion of Participants With COVID-19-related MAVs by Day 29
Proportion of Participants With COVID-19-related Medically Attended Visits (MAVs) or All-cause Death by Day 29
Time to Sustained Alleviation of Targeted COVID-19 Symptoms
Day 30
Percentage Of Participants With Treatment-Emergent Adverse Events
Therapeutic procedure

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

GS-5245
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

2300 Total Participants · 2 Treatment Groups

Primary Treatment: GS-5245 · Has Placebo Group · Phase 3

GS-5245
Drug
Experimental Group · 1 Intervention: GS-5245 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: GS-5245 Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: first dose date up to day 5 plus 30 days

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,018 Previous Clinical Trials
754,099 Total Patients Enrolled
Gilead Study DirectorStudy DirectorGilead Sciences
320 Previous Clinical Trials
178,726 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have signs/symptoms of COVID-19.